Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Controlled Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) Compared With Nplate® (Amgen, the Netherlands) in Patients With Persistent or Early Immune Thrombocytopenia

NCT06497036 is registered in ClinicalTrials.gov with Geropharm as lead sponsor.

NCT NCT06497036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06497036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Controlled Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) Compared With Nplate® (Amgen, the Netherlands) in Patients With Persistent or Early Immune Thrombocytopenia
Lead sponsor
Geropharm
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 4, 2023
Completion date
March 31, 2028
Enrollment
160 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

drug effect, immunogenicity, safety issues